Fluctuations in mood or anxiety (in rare cases)
If left untreated, metabolic syndrome can lead to heart disease, Type 2 diabetes, and stroke
Shares of several companies tied to the obesity drug boom moved lower following Amazon's Tuesday announcement, including Hims & Hers Health, Viking Therapeutics, Amgen and Septerna.
0.6% with placebo at 68 weeks Dose escalation schedule / 0.25 mg weekly for 4 weeks, escalating to 2.4 mg over 16 weeks AAP guideline threshold / pharmacotherapy considered at age 12 or older with obesity Growth monitoring / required at every visit for all pediatric patients on GLP-1 therapy Off-label use in under-12 / not recommended by any major guideline body FDA Approval Covers Ages 12 and Up Only Wegovy received expanded approval from the FDA in December 2022 for adolescents aged 12 years and older with a body mass index at or above the 95th percentile for age and sex [1]
As I also wrote for the BBC last year, the so-called "Ozempic rebound" effect where patients immediately regain weight when treatment ceases, remains a challenge, especially in cases where people are paying for treatment on a private basis and can't afford to continue
I have struggled with being overweight most of my life, and I realize that not all plans and methods are a fit for everyone
